Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma

被引：0

作者：

Ledford, Aubrey ^{[1
]}

Rodriguez, Analiz ^{[2
]}

Lipinski, Lindsay ^{[3
]}

Abad, Ajay ^{[3
]}

Fenstermaker, Robert ^{[3
]}

Edenfield, Jeffrey ^{[4
]}

Kanos, Charles ^{[5
]}

Redjal, Navid ^{[6
]}

Mansouri, Alireza ^{[7
]}

Zacharia, Brad ^{[7
]}

Butowski, Nicholas ^{[8
]}

Liu, Jesse ^{[9
]}

Han, Seunggu J. ^{[9
,12
]}

Ziu, Mateo ^{[10
]}

Cohen, Adam L. ^{[11
]}

Fabiano, Andrew J. ^{[3
]}

Miles, Katherine ^{[1
]}

Rayner, Melissa ^{[1
]}

Thompson, Jayla ^{[1
,13
]}

Tollison, Kelley ^{[1
]}

Azimzadeh, Pedram ^{[1
]}

Holmes, Lillia ^{[1
]}

Gevaert, Matthew ^{[1
]}

DesRochers, Teresa M. ^{[1
]}

机构：

[1] Kiyatec Inc, 2 N Main St, Greenville, SC 29601 USA

[2] Univ Arkansas Med Sci, Dept Neurosurg, Little Rock, AR 72205 USA

[3] Roswell Park Comprehens Canc Ctr, Dept Neurosurg, Dept Neurooncol, Buffalo, NY 14203 USA

[4] Prisma Hlth Canc Inst, Inst Translat Oncol Res, Greenville, SC 29605 USA

[5] Prisma Hlth Southeastern Neurosurg & Spine Inst, Dept Neurosurg, Greenville, SC 29605 USA

[6] Capital Hlth Inst Neurosci, Dept Neurosurg Oncol, Pennington, NJ 08534 USA

[7] Penn State Hershey Med Ctr, Dept Neurosurg, Hershey, PA 17033 USA

[8] Univ Calif San Francisco, Dept Neurooncol, San Francisco, CA 94143 USA

[9] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA

[10] Inova Healthcare Syst, Dept Neurosurg, Falls Church, VA 22042 USA

[11] Inova Schar Canc Inst, Dept Med Oncol, Fairfax, VA 22031 USA

[12] Stanford Med, Dept Neurol Surg, Palo Alto, CA USA

[13] IQVIA, Durham, NC 27703 USA

来源：

SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期

关键词：

MGMT PROMOTER METHYLATION; CENTRAL-NERVOUS-SYSTEM; ADJUVANT TEMOZOLOMIDE; GLIOBLASTOMA PATIENTS; RADIOTHERAPY; CONCOMITANT; MUTATIONS; TUMORS; IDH1; TIME;

D O I：

10.1038/s41598-024-68801-0

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Patients with high-grade glioma (HGG) have an extremely poor prognosis compounded by a lack of advancement in clinical care over the past few decades. Regardless of classification, most newly diagnosed patients receive the same treatment, radiation and temozolomide (RT/TMZ). We developed a functional precision oncology test that prospectively identifies individual patient's response to this treatment regimen. Tumor tissues isolated from patients with newly diagnosed HGG enrolled in 3D PREDICT REGISTRY were evaluated for response to chemotherapeutic agents using the 3D Predict (TM) Glioma test. Patients receiving RT/TMZ were followed for 2 years. Clinical outcomes including imaging, assessments, and biomarker measurements were compared to patient matched test-predicted therapy response. Median survival between test-predicted temozolomide responders and test-predicted temozolomide non-responders revealed a statistically significant increase in progression-free survival when using the test to predict response across multiple subgroups including HGG (5.8 months), glioblastoma (4.7 months), and MGMT unmethylated glioblastoma (4.7 months). Overall survival was also positively separated across the subgroups at 7.6, 5.1, and 6.3 months respectively. The strong correlation of 3D Predict Glioma test results with clinical outcomes demonstrates that this functional test is prognostic in patients treated with RT/TMZ and supports aligning clinical treatment to test-predicted response across varying HGG subgroups.

引用

页数：16

共 44 条

[21] IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy [J].

Li, Hailong ;

Li, Jiye ;

Cheng, Gang ;

Zhang, Panning ;

Li, Xuezhen .

CLINICAL NEUROLOGY AND NEUROSURGERY, 2016, 151 :31-36

[22] The 2021 WHO Classification of Tumors of the Central Nervous System: a summary [J].

Louis, David N. ;

Perry, Arie ;

Wesseling, Pieter ;

Brat, Daniel J. ;

Cree, Ian A. ;

Figarella-Branger, Dominique ;

Hawkins, Cynthia ;

Ng, H. K. ;

Pfister, Stefan M. ;

Reifenberger, Guido ;

Soffietti, Riccardo ;

von Deimling, Andreas ;

Ellison, David W. .

NEURO-ONCOLOGY, 2021, 23 (08) :1231-1251

[23] Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial [J].

Malmstrom, Annika ;

Gronberg, Bjorn Henning ;

Marosi, Christine ;

Stupp, Roger ;

Frappaz, Didier ;

Schultz, Henrik ;

Abacioglu, Ufuk ;

Tavelin, Bjorn ;

Lhermitte, Benoit ;

Hegi, Monika E. ;

Rosell, Johan ;

Henriksson, Roger .

LANCET ONCOLOGY, 2012, 13 (09) :916-926

[24] MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges [J].

Mansouri, Alireza ;

Hachem, Laureen D. ;

Mansouri, Sheila ;

Nassiri, Farshad ;

Laperriere, Normand J. ;

Xia, Daniel ;

Lindeman, Neal I. ;

Wen, Patrick Y. ;

Chakravarti, Arnab ;

Mehta, Minesh P. ;

Hegi, Monika E. ;

Stupp, Roger ;

Aldape, Kenneth D. ;

Zadeh, Gelareh .

NEURO-ONCOLOGY, 2019, 21 (02) :167-178

[25] Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis [J].

Marenco-Hillembrand, Lina ;

Wijesekera, Olindi ;

Suarez-Meade, Paola ;

Mampre, David ;

Jackson, Christina ;

Peterson, Jennifer ;

Trifiletti, Daniel ;

Hammack, Julie ;

Ortiz, Kyle ;

Lesser, Elizabeth ;

Spiegel, Matthew ;

Prevatt, Calder ;

Hawayek, Maria ;

Quinones-Hinojosa, Alfredo ;

Chaichana, Kaisorn L. .

JOURNAL OF NEURO-ONCOLOGY, 2020, 147 (02) :297-307

[26]

National Comprehensive Cancer N. Central Nervous System Cancers NCCN Evidence Blocks, 2022, NCCN Guidelines, V2

[27] Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers [J].

Ntafoulis, Ioannis ;

Kleijn, Anne ;

Ju, Jie ;

Jimenez-Cowell, Kevin ;

Fabro, Federica ;

Klein, Michelle ;

Yen, Romain Tching Chi ;

Balvers, Rutger K. ;

Li, Yunlei ;

Stubbs, Andrew P. ;

Kers, Trisha V. ;

Kros, Johan M. ;

Lawler, Sean E. ;

Beerepoot, Laurens V. ;

Kremer, Andreas ;

Idbaih, Ahmed ;

Verreault, Maite ;

Byrne, Annette T. ;

O'Farrell, Alice C. ;

Connor, Kate ;

Biswas, Archita ;

Salvucci, Manuela ;

Prehn, Jochen H. M. ;

Lambrechts, Diether ;

Dilcan, Gonca ;

Lodi, Francesca ;

Arijs, Ingrid ;

van den Bent, Martin J. ;

Dirven, Clemens M. F. ;

Leenstra, Sieger ;

Lamfers, Martine L. M. .

BRITISH JOURNAL OF CANCER, 2023, 129 (08) :1327-1338

[28] CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019 [J].

Ostrom, Quinn T. ;

Price, Mackenzie ;

Neff, Corey ;

Cioffi, Gino ;

Waite, Kristin A. ;

Kruchko, Carol ;

Barnholtz-Sloan, Jill S. .

NEURO-ONCOLOGY, 2022, 24 :v1-v95

[29] Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma [J].

Park, Ae Kyung ;

Kim, Pora ;

Ballester, Leomar Y. ;

Esquenazi, Yoshua ;

Zhao, Zhongming .

NEURO-ONCOLOGY, 2019, 21 (01) :59-70

[30] IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma [J].

Qi SongTao ;

Yu Lei ;

Gui Si ;

Ding YanQing ;

Han HuiXia ;

Zhang XueLin ;

Wu LanXiao ;

Yao Fei .

CANCER SCIENCE, 2012, 103 (02) :269-273

← 1 2 3 4 5 →